Abstract: A method of capturing human immunoglobulin Fc domains in a biofluid sample is provided. The method includes providing an affinity capture device. The affinity capture device includes a surface having an aptamer that is at least 80% identical to SEQ ID NO 1 immobilized onto the surface of the affinity capture device. The biofluid sample is diluted with a binding buffer. The binding buffer includes (A) tris(hydroxymethyl)aminomethane (Tris), trimethylamine (TES), 2-ethanesulfonic acid (MES), or 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES); (B) a magnesium cation at a concentration between about 10 ?M to about 20 mM; and (C) a total monovalent cation concentration from 0 to no greater than 100 mM. The human immunoglobulin Fc domains in the biofluid sample are adsorbed to the aptamer with the binding buffer.
Abstract: Aspects of the disclosure relate to methods for determining whether or a subject is likely to respond to certain adoptive cell therapies (e.g., chimeric antigen receptor (CAR) T-cell therapy, etc.). In some embodiments, the methods comprise the steps of identifying a subject as having a tumor microenvironment (TME) type based upon a molecular-functional (MF) expression signature of the subject, and determining whether or not the subject is likely to respond to a chimeric antigen receptor (CAR) T-cell therapy based upon the TME type. In some embodiments, the methods comprise determining the lymphoma microenvironment (LME) type of a lymphoma (e.g., Diffuse Large B cell lymphoma (DLBCL)) subject and identifying the subject's prognosis based upon the LME type determination.
Type:
Grant
Filed:
July 6, 2021
Date of Patent:
January 31, 2023
Assignee:
BostonGene Corporation
Inventors:
Nikita Kotlov, Georgy Sagaradze, Alexander Bagaev, Grigorii Nos, Lev Bedniagin, Dmitry Kravchenko, Anna Gribkova
Abstract: The present disclosure relates to a Proteomics-to-Genomics approach allows for in silico validation of biomarkers and drug targets. Biomarkers having high prognostic value in predicting cancer patient populations that may benefit from mitochondrial biogenesis inhibitor therapy may be identified under the present approach. Also disclosed are methods for identifying candidates for anti-mitochondrial therapy, and in particular mitochondrial biogenesis inhibitor therapy. Diagnostic kits including reagents for determining transcripts or probes of high prognostic value are also disclosed. Additionally, mitochondrial biogenesis inhibitors may be used as anti-cancer agents for diverse oncogenic stimuli, including for example, c-MYC and H-Ras oncogenes, as well as environmental stimuli such as, for example rotenone.
Abstract: Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A- is a Stretcher unit, and p is from about 3 to about 5.
Abstract: Disclosed herein are methods of treating a subject with an estrogen receptor-positive (ER+) breast cancer comprising obtaining a sample of the breast cancer from the subject; determining a level of E-cadherin in the sample is reduced compared to a control; and administering a therapeutically effective amount of an IGF1R pathway inhibitor and an endocrine therapeutic. Also disclosed herein are methods to treat a cancer in a subject comprising administering a therapeutically effective amount of an IGF1R pathway inhibitor and an E-cadherin inhibitor. Also disclosed are methods to predict the likelihood a subject with a breast cancer will respond therapeutically to a treatment comprising administering an IGF1R pathway inhibitor, the method comprising obtaining a sample of the cancer from the subject; and determining a level of E-cadherin in the sample.
Type:
Grant
Filed:
February 26, 2019
Date of Patent:
January 10, 2023
Assignee:
University Of Pittsburgh-Of The Commonwealth System Of Higher Education
Inventors:
Adrian Lee, Alison Nagle, Steffi Oesterreich
Abstract: It is an object of the present invention to provide, for instance, a method for evaluating a function, such as transforming potential, of multiple different genes of interest, and a method capable of evaluating drug sensitivity of a subject having each gene of interest.
Type:
Grant
Filed:
March 30, 2018
Date of Patent:
January 3, 2023
Assignee:
The University of Tokyo
Inventors:
Hiroyuki Mano, Shinji Kohsaka, Masachika Ikegami
Abstract: This document relates to methods and materials for detecting premalignant and malignant neoplasms. For example, methods and materials for determining whether or not a stool sample from a mammal contains nucleic acid markers or polypeptide markers of a neoplasm are provided.
Type:
Grant
Filed:
January 9, 2020
Date of Patent:
December 20, 2022
Assignee:
Mayo Foundation for Medical Education and Research
Inventors:
William R. Taylor, Jonathan J. Harrington, Patrick S. Quint, Hongzhi Zou, Harold R. Bergen, III, David I. Smith, David A. Ahlquist
Abstract: Cancer patients make antibodies to tumor-derived proteins that are potential biomarkers for early detection. Twenty-eight antigens have been identified as potential biomarkers for the early detection of basal-like breast cancer (Tables 1, 2). Also, a 13-AAb classifier has been developed that differentiate patients with BLBC from healthy controls with 33% sensitivity at 98% specificity (Table 3).
Type:
Grant
Filed:
January 15, 2020
Date of Patent:
December 13, 2022
Assignees:
ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Inventors:
Joshua LaBaer, Jie Wang, Ji Qui, Garrick Wallstrom, Karen Anderson, Jin Park, Jonine Figueroa
Abstract: The invention is a method of predicting response to therapy in a colorectal cancer patient, the method comprising analysis of circulating tumor DNA from a patient's sample.
Type:
Grant
Filed:
August 7, 2019
Date of Patent:
December 6, 2022
Assignee:
ROCHE SEQUENCING SOLUTIONS, INC.
Inventors:
John Lee, Alexander Lovejoy, John Palma, Ulrich-Peter Rohr, Lijing Yao, Stephanie Yaung
Abstract: The present invention relates to a method of producing low viscous and highly concentrated biopharmaceutical drug products comprising a biomolecule of interest, the method comprising: (a) a first phase of preparing a drug substance of the biomolecule of interest, said first phase comprising at least one processing step selected from (a1) harvesting, (a2) purification, (a3) re-buffering, and (a4) enrichment, wherein said at least one processing step in this first phase is carried out in the presence of a composition comprising at least three amino acids, wherein the combination of said at least three amino acids provides at least one positively charged functional group, at least one anti-oxidative functional group, at least one osmolytic function, and at least one buffering function, and (b) a second phase of further processing the drug substance prepared in (a) to obtain a low viscous and highly concentrated biopharmaceutical drug product, said second phase comprising at least one processing step selected fro
Type:
Grant
Filed:
September 15, 2017
Date of Patent:
November 29, 2022
Assignee:
Leukocare AG
Inventors:
Martin Scholz, Kristina Kemter, Jens Altrichter, Thomas Kriehuber
Abstract: The present disclosure provides a bispecific single-chain antibody, recombinant oncolytic virus for expressing same and virus composition. The antibody named BiTEs-PD-L1 is a bispecific antibody capable of simultaneously binding CD3 and PD-L1 on the surfaces of tumor cells, and it can effectively activate T cells and guide T cells to kill tumor cells. The oncolytic virus oHSV2-BiTEs-PD-L1 is further developed by utilizing the BiTEs-PD-L1, it can reduce frequency and dosage of the administration. The present disclosure also confirmed several virus compositions with excellent antitumor effect.
Type:
Grant
Filed:
January 5, 2022
Date of Patent:
November 22, 2022
Assignee:
BINHUI BIOPHARMACEUTICAL CO., LTD.
Inventors:
Binlei Liu, Linkang Cai, Runyang Wang, Siqi Zhang, Han Hu
Abstract: The present invention relates to a method of diagnosing Head and Neck Squamous Cell Carcinoma (HNSCC) in an individual. In addition, the present invention relates to a method of providing a survival prognosis to an individual suffering from Head and Neck Squamous Cell Carcinoma (HNSCC). Moreover, the present invention relates to a kit for performing the above-mentioned methods.
Type:
Grant
Filed:
April 6, 2020
Date of Patent:
November 8, 2022
Assignee:
OTTO-VON-GUERICKE-UNIVERSITÄT MAGDEBURG
Inventors:
Johannes Haybäck, Anna Maria Cyran, Christoph Arens, Michael Naumann
Abstract: The state of protein phosphorylation and glycosylation can be key determinants of cellular physiology such as early stage cancer, but the development of phosphoproteins and/or glycoproteins in biofluids for disease diagnosis remains elusive. Here we demonstrate, for the first time, a strategy to isolate and identify phosphoproteins/glycoproteins in extracellular vesicles (EVs) from human plasma as potential markers to differentiate disease from healthy states. We identified close to 10,000 unique phosphopeptides in EVs by isolating from small volume of plasma samples. Using label-free quantitative phosphoproteomics, we identified 144 phosphoproteins in plasma EVs that are significantly higher in patients diagnosed with breast cancer than in healthy controls. Several novel biomarkers were validated in individual patients using Paralleled Reaction Monitoring for targeted quantitation. Similarly a group of glycoproteins in plasma EVs are identified.
Type:
Grant
Filed:
January 8, 2018
Date of Patent:
October 25, 2022
Assignee:
Purdue Research Foundation
Inventors:
Weiguo Andy Tao, Anton B. Ilyuk, Hillary Andaluz, I-Hsuan Chen, Li Pan
Abstract: The present disclosure provides a heterodimeric, conditionally active chimeric antigen receptor (CAR), and a nucleic acid comprising a nucleotide sequence encoding the CAR. The present disclosure provides cells genetically modified to produce the CAR. A CAR of the present disclosure can be used in various methods, which are also provided.
Type:
Grant
Filed:
March 19, 2020
Date of Patent:
October 25, 2022
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Inventors:
Chia-Yung Wu, James Onuffer, Wendell A. Lim
Abstract: The present invention relates to methods for detecting, diagnosing, prognosing, monitoring, and treating a patient with hepatocellular carcinoma. In particular, the invention provides diagnostic markers for the detection and treatment of patients who would benefit from immunotherapy, i.e., patient who would be most responsive to immunotherapy.
Type:
Grant
Filed:
June 14, 2018
Date of Patent:
October 18, 2022
Assignee:
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Inventors:
Daniela Sia, Josep Maria Llovet I Bayer, Augusto Villanueva-Rodriguez
Abstract: It has been discovered that the human GT198 gene (gene symbol PSMC3IP) at chromosome 17q21 acts as a tumor suppressor. The mutation of the GT198 gene causes the increased dominant negative splice variant activity and leads to the loss of wild type GT198 function, and in turn, induces breast and ovarian cancers. One embodiment provides compositions and methods for treating or alleviating one or more symptoms associated with cancer due to the GT198 gene mutations. Another embodiment provides methods and compositions for detecting cancer due to the mutation of the GT198 gene. Still another embodiment provides methods for identifying compounds, antibodies and natural product molecules that are useful for treating cancer due to the mutations of the GT198 gene. Preferably the disclosed compositions antagonize or interfere with the biological activity of splice variants of GT198.
Abstract: The present invention generally relates to the fields of cancer therapy and cancer prevention. More particularly, the present invention generally relates to a diagnostic marker for predicting the efficacy of topoisomerase I (topo I) inhibitors in the treatment of cancers. More specifically, the present invention relates to methods, machines, computer systems, computable readable media and kits which can be used to identify and determine the effectiveness of topoisomerase I (topo I) inhibitors in the treatment of cancers, and in some embodiments, the level of sensitivity or resistance of a tumor cell to a topoisomerase I inhibitor, such as camptothecin (CPT), or CPT analogues such as topotecan and irinotecan and derivatives thereof. More specifically, the present invention related to methods, machines, computer systems, computable readable media and kits which can be used to determine a mutation in the BRCA1 gene, e.g.
Abstract: The invention provides methods of dosing for the treatment of cancers, such as B cell proliferative disorders, with anti-cluster of differentiation 20 (CD20)/anti-cluster of differentiation 3 (CD3) bispecific antibodies.
Abstract: Provided is a method for evaluating the progression of glioma in an individual comprising monitoring the levels of circulating exosomes that are positive for survivin and a glial marker (such as glial fibrillary acidic protein). An increase in the level of such exosomes is indicative of poor prognosis. Levels of circulating exosomes that are positive for survivin and glial marker can also be used for evaluating the efficacy of a therapy for glioma in an individual, and modifying the therapy or introducing additional therapy if levels of such exosomes are found to be increasing.
Type:
Grant
Filed:
December 18, 2017
Date of Patent:
October 11, 2022
Assignee:
Health Research, Inc.
Inventors:
Robert A. Fenstermaker, Michael J. Ciesielski